# US 2008/0075738 A1 · Chimeric T helper-B cell peptide vaccine for Japanese encephalitis virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075738 A1
- Document ID: US20080075738A1
- Status: Published application
- Kind: A1
- Application number: 11/979,192
- Filed: 2007-10-31
- Published: 2008-03-27
- Earliest claimed: 2001-01-05
- Assignees: Secretary, Department of Biotechnology; National Institute of Virology (Indian Council of Medical Research); University of Pune
- Inventors: M. Gore; Ashok Kolaskar; S. Dewasthaly; Urmila Kulkarani-Kale; Sangeeta Sawant
- Web page: https://patentgrep.com/patent/US20080075738A1

## CPC

- C07K 14/005: from viruses
- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/6081: {Albumin; Keyhole limpet haemocyanin [KLH]}
- C07K 2319/00: Fusion polypeptide
- C12N 2770/24122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A vaccine composition for humans and animals against Japanese encephalitis virus infection is a composition which comprises a chimeric synthetic peptide consisting of a B cell epitope linked to a T-helper cell epitope from Japanese encephalitis proteins, wherein the chimeric peptide is in an amount sufficient to induce protective immunity against Japanese encephalitis virus infection. For example, the B cell epitope may be SEQ ID NO:46, 84 or 85; and the T-helper cell epitope may be SEQ ID NO:77, 82 or 83.

## Claims

### Claim 1

A synthetic polypeptide consisting of a virus-neutralizing antibody-inducing B-cell epitope linked to a T-helper cell epitope, wherein the epitopes are from proteins of Japanese Encephalitis Virus.

### Claim 2 (depends on 1)

The synthetic polypeptide of claim 1, wherein
a. the B-cell epitope has the sequence NHGNYSAQVGASQ (SEQ ID NO:46), and the T-helper cell epitope has the sequence SVRTTTDSGKLITDG (SEQ ID NO:82);
b. the B-cell epitope has the sequence NHGNYSAQVGASQ (SEQ ID NO:46), and the T-helper cell epitope has the sequence EAWLDSTKATG (SEQ ID NO:83);
c. the B-cell epitope has the sequence PTLDVRMINIE (SEQ ID NO:84), and the T-helper cell epitope has the sequence EAWLDSTKATG (SEQ ID NO:83); or
d. the B-cell epitope has the sequence TLDVRMINIE (SEQ ID NO:85), and the T-helper cell epitope has the sequence SVRTTTDSGKLITDG (SEQ ID NO:82).

### Claim 3 (depends on 1)

The synthetic polypeptide of claim 1, wherein the sequence of the polypeptide is:
a.
NHGNYSAQVGASQ-SVRTTTDSGKLITDG,
(SEQ ID NO: 86)
b.
NHGNYSAQVGASQ-EAWLDSTKATG,
(SEQ ID NO: 87)
c.
PTLDVRMINIE-EAWLDSTKATG,
(SEQ ID NO: 88)
or
d.
SVRTTTDSGKLITDG-TLDVRMINIE.
(SEQ ID NO: 89)

### Claim 4 (depends on 1)

The synthetic polypeptide of claim 1, wherein
the B-cell epitope has a sequence from the envelope glycoprotein, Egp, selected from the group consisting of 149-SENHGNYSAQVGASQ-163 (SEQ ID NO:1), 149-SENHGNYSAQVGASQAAKF-167 (SEQ ID NO:3), 39-PTLDVRMINIEA-50 (SEQ ID NO:4), and 273-EYSSSVKLTSG-283 (SEQ ID NO:5); and
the T-helper cell epitope has a sequence selected from the group consisting of Egp 429-SIGGVFNSIGKAVHQVF-445 (SEQ ID NO:63), Egp 346-HVLGRLTTVN-355 (SEQ ID NO:67), membrane protein M 17-EAWLDSTKAT-26 (SEQ ID NO:68), nonstructural protein-1 sequences, NS-1 297-SVRTTTDSGKLITD-310 (SEQ ID NO:71), NS-1 156-EDFGFGITSTRV-167 (SEQ ID NO:72), and NS-1 404-TDLARYVVL-412 (SEQ ID NO:73).

### Claim 5 (depends on 1)

An immunogenic composition comprising one or more synthetic polypeptides of claim 1.

### Claim 6 (depends on 2)

An immunogenic composition comprising one or more synthetic polypeptides of claim 2.

### Claim 7 (depends on 3)

An immunogenic composition comprising one or more synthetic polypeptides of claim 3.

### Claim 8 (depends on 4)

An immunogenic composition comprising one or more synthetic polypeptides of claim 4.

### Claim 9 (depends on 5)

The immunogenic composition of claim 5, which is a vaccine that is protective against infection by Japanese Encephalitis Virus.

### Claim 10 (depends on 6)

The immunogenic composition of claim 6, which is a vaccine that is protective against infection by Japanese Encephalitis Virus.

### Claim 11 (depends on 7)

The immunogenic composition of claim 7, which is a vaccine that is protective against infection by Japanese Encephalitis Virus.

### Claim 12 (depends on 8)

The immunogenic composition of claim 8, which is a vaccine that is protective against infection by Japanese Encephalitis Virus.
